Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a tetracycline designed for the treatment of moderate to severe acne vulgaris. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and contract with Biomedical Advanced Research and Development Authority to support the development of NUZYRA for the treatment of pulmonary anthrax. It also has license agreement with Tetraphase Pharmaceuticals, Inc. to develop, import, and sell the XERAVATM product, which is used for the treatment of complicated intra-abdominal infections caused by bacteria. The company was founded in 1996 and is headquartered in Boston, Massachusetts.
IPO Year:
Exchange: NASDAQ
Website: paratekpharma.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/2/2023 | $7.00 → $5.00 | Buy | Jefferies |
| 4/17/2023 | $24.00 | Buy | BTIG Research |
| 2/10/2022 | $11.00 | Buy → Strong Buy | WBB Securities |
| 11/9/2021 | $28.00 → $27.00 | Buy | HC Wainwright & Co. |
4 - Paratek Pharmaceuticals, Inc. (0001178711) (Issuer)
4 - Paratek Pharmaceuticals, Inc. (0001178711) (Issuer)
4 - Paratek Pharmaceuticals, Inc. (0001178711) (Issuer)
4 - Paratek Pharmaceuticals, Inc. (0001178711) (Issuer)
4 - Paratek Pharmaceuticals, Inc. (0001178711) (Issuer)
4 - Paratek Pharmaceuticals, Inc. (0001178711) (Issuer)
4 - Paratek Pharmaceuticals, Inc. (0001178711) (Issuer)
4 - Paratek Pharmaceuticals, Inc. (0001178711) (Issuer)
4 - Paratek Pharmaceuticals, Inc. (0001178711) (Issuer)
4 - Paratek Pharmaceuticals, Inc. (0001178711) (Issuer)
Submission status for PARATEK PHARMS INC's drug NUZYRA (SUPPL-10) with active ingredient OMADACYCLINE TOSYLATE has changed to 'Approval' on 05/27/2021. Application Category: NDA, Application Number: 209817, Application Classification: Efficacy
Submission status for PARATEK PHARMS INC's drug NUZYRA (SUPPL-11) with active ingredient OMADACYCLINE TOSYLATE has changed to 'Approval' on 05/27/2021. Application Category: NDA, Application Number: 209816, Application Classification: Efficacy
Submission status for PARATEK PHARMS INC's drug NUZYRA (SUPPL-11) with active ingredient OMADACYCLINE TOSYLATE has changed to 'Approval' on 01/11/2021. Application Category: NDA, Application Number: 209817, Application Classification: Labeling
Submission status for PARATEK PHARMS INC's drug NUZYRA (SUPPL-12) with active ingredient OMADACYCLINE TOSYLATE has changed to 'Approval' on 01/11/2021. Application Category: NDA, Application Number: 209816, Application Classification: Labeling
15-12G - Paratek Pharmaceuticals, Inc. (0001178711) (Filer)
EFFECT - Paratek Pharmaceuticals, Inc. (0001178711) (Filer)
SC 13E3/A - Paratek Pharmaceuticals, Inc. (0001178711) (Subject)
POS AM - Paratek Pharmaceuticals, Inc. (0001178711) (Filer)
S-8 POS - Paratek Pharmaceuticals, Inc. (0001178711) (Filer)
S-8 POS - Paratek Pharmaceuticals, Inc. (0001178711) (Filer)
S-8 POS - Paratek Pharmaceuticals, Inc. (0001178711) (Filer)
S-8 POS - Paratek Pharmaceuticals, Inc. (0001178711) (Filer)
S-8 POS - Paratek Pharmaceuticals, Inc. (0001178711) (Filer)
S-8 POS - Paratek Pharmaceuticals, Inc. (0001178711) (Filer)
BOSTON, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) today announced that the Company's independent directors of the Board have appointed Jeffrey Stein, PhD as its first Lead Independent Director, effective December 8, 2022. Dr. Stein was selected unanimously by the independent directors of the Board, in recognition of his extensive leadership experience, in-depth knowledge of Paratek and the business of the anti-infective industry, strong financial and operational track record, and demonstrated independent judgment, integrity and commitment to the role. Having served as a director of Paratek since its emergence as a public company in 2014, Dr. Stein
NORTH BILLERICA, Mass., March 01, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("the Company") (NASDAQ:LNTH), today announced the appointment of Ms. Minnie Baylor-Henry, Esq., a renowned expert in regulatory affairs and compliance in the life sciences industry, to Lantheus' Board of Directors ("Board"), effective immediately. As an independent director, Ms. Baylor-Henry will serve as a member of the Board's Compensation Committee and the Science and Technology Committee. Following the appointment of Ms. Baylor-Henry, the Board will be comprised of nine directors, eight of whom are independent. "We are pleased to welcome Minnie Baylor-Henry, a highly respected authority in FDA law an
- Evan Loh, M.D., Jonathan Leff, and Jana Jensen, Ph.D., Appointed Directors of APT - Adaptive Phage Therapeutics, Inc. ("APT"), a clinical-stage biotechnology company dedicated to providing therapies to treat infectious diseases, today announced the appointment of Evan Loh, M.D., CEO of Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK), Jonathan Leff, Partner at Deerfield Management, and Jana Jensen, Ph.D., Chief Operating Officer at Deerfield Discovery and Development, to the company's Board of Directors. "We are delighted to welcome Evan, Jonathan, and Jana to APT's Board, as we expand our team following the successful completion of our $40.75 million Series B financing," said Greg Merril, A
BOSTON, June 14, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use, today announced the appointment of Minnie Baylor-Henry, J.D., a recognized leader in the area of food and drug laws and regulations, to the company's Board of Directors. "We're delighted to welcome Minnie to Paratek's Board of Directors," said Michael Bigham, Chairman of the Board for Paratek. "She brings extensive expertise and unique perspectives from her work with top glo
BOSTON, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government and military use, today announced that on November 30, 2020, the Company granted stock options and restricted stock units to one new employee of the Company. These awards were granted pursuant to the Paratek Pharmaceuticals, Inc. 2017 Inducement Plan, as amended, which was approved by the Company's board of directors on June 15, 2017, under Rule 5635(c)(4) of the NASDAQ Listing Rules, for equity
-- NUZYRA® (omadacycline) Net U.S. Sales of $33.8 Million from the Core Commercial Business, a 35% Increase Over Second Quarter 2022 --Previously Announced Agreement to be Acquired by Gurnet Point Capital and Novo Holdings A/S; Transaction Expected to Close in the Third Quarter BOSTON, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK), ("Paratek" or "the Company"), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government and military use, today reported financial results and provided an update on corpora
-- NUZYRA® (omadacycline) Generated Net U.S. Sales of $26.2 Million from the Core Commercial Business, a 32% Increase Over First Quarter 2022 -- Company Reiterates Full-Year Revenue Guidance of $143 to $158 Million -- Announces Full-Year R&D and SG&A Expense Guidance of $160 to $170 Million, Approximately $20 Million in Savings Over Annualized Fourth Quarter 2022 Spend Rate1, Enabled by Operational Efficiencies BOSTON, May 09, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats fo
BOSTON, May 01, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) today announced that the company will host a conference call and live audio webcast on Tuesday, May 9 at 4:30 p.m. EDT to report financial results for first quarter 2023.The audio webcast can be accessed under "Events and Presentations" in the Investor Relations section of the Company's website at www.ParatekPharma.com.Domestic investors wishing to participate in the call will dial: 800-920-3371 and international investors will dial: +1-212-231-2909. The conference ID is 22026760. Investors can also access the call at: https://viavid.webcasts.com/starthere.jsp?ei=1611304&tp_key=5fe62a51b9About Paratek Phar
-- NUZYRA® (omadacycline) Generated Net U.S. Sales of $98.7 Million from the Core Commercial Business, a 45% Increase Over the Prior Year -- Continued Progress on the Rare Disease Nontuberculous Mycobacteria (NTM) & BARDA Project BioShield Anthrax Programs BOSTON, March 16, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK), today reported financial results and provided an update on corporate activities for the fourth quarter and full-year ended December 31, 2022. Paratek generated total revenue of $160.3 million, primarily as a result of strong growth in NUZYRA® commercial revenue. NUZYRA generated full-year net U.S. sales of $136.8 million in 2022, comprised of $9
BOSTON, March 08, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) today announced that the company will host a conference call and live audio webcast on Thursday, March 16, 2023 at 8:30 a.m. EST to provide a corporate update and report its financial results for fourth quarter and full year 2022. The audio webcast can be accessed under "Events and Presentations" in the Investor Relations section of the Company's website at www.ParatekPharma.com. Domestic investors wishing to participate in the call will dial: 877-407-0792 and international investors will dial: 201-689-8263. The conference ID is 13736677. Investors can also access the call at: https://viavid.webcasts.
-- NUZYRA® (omadacycline) Generated Net U.S. Sales of $25.5 Million from the Core Commercial Business, a 31% increase from $19.4 Million in Third Quarter 2021 -- Initiated Rabbit Pilot Efficacy Study for the Treatment of Pulmonary Anthrax -- Announced Commercial Availability of U.S.-manufactured NUZYRA Tablets BOSTON, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK), today reported financial results and provided an update on corporate activities for the quarter ended September 30, 2022. "We are pleased to report another strong quarter of growth in NUZYRA's core commercial business, as evidenced by the 31% increase in net U.S. sales compared to the same per
BOSTON, Oct. 25, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) today announced that the company will host a conference call and live audio webcast on Thursday, Nov. 3 at 4:30 p.m. ET to report its financial results for the third quarter of 2022. The audio webcast can be accessed under "Events and Presentations" in the Investor Relations section of the Company's website at www.ParatekPharma.com. Domestic investors wishing to participate in the call should dial 800-458-4121 and international investors should dial +1-646-828-8193. The conference ID is 7165992. Investors can also access the event at: https://viavid.webcasts.com/starthere.jsp?ei=1577240&tp_key=22e88571f9.
-- NUZYRA® (omadacycline) Generated Net U.S. Sales of $25.1 Million from the Core Commercial Business, a 68% increase over Second Quarter 2021 -- Company Reiterates Full Year 2022 Financial Guidance BOSTON, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK), today reported financial results and provided an update on corporate activities for the quarter ended June 30, 2022. "The strong year-over-year growth of NUZYRA's core commercial business is a result of accelerating product demand and the disciplined execution of our community sales force expansion, which was initiated in the first quarter of 2021," said Evan Loh, M.D., chief executive officer
BOSTON, July 25, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) today announced that the company will host a conference call and live audio webcast on Wednesday, Aug. 3 at 4:30 p.m. ET to report its financial results for the second quarter of 2022. The audio webcast can be accessed under "Events and Presentations" in the Investor Relations section of the Company's website at www.ParatekPharma.com. Domestic investors wishing to participate in the call should dial 877-300-8521 and international investors should dial +1-412-317-6026. The conference ID is 10169245. Investors can also access the event at: https://viavid.webcasts.com/starthere.jsp?ei=1559934&tp_key=28146
-- NUZYRA® (omadacycline) Generated Net U.S. Sales of $19.9 Million from the Core Commercial Business, a 51% Increase over First Quarter 2021 -- Omadacycline Demonstrated Potent In Vitro Efficacy Against Mycobacterium Avium Complex (MAC) in a Hollow Fiber Model BOSTON, May 04, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) today reported financial results and provided an update on corporate activities for the quarter ended March 31, 2022. "Our commercial execution continues to be strong, as demonstrated by the 51% year-over-year first quarter growth from the core NUZYRA commercial business. As the Omicron wave receded, we experienced accelerated product demand thro
SC 13G - Paratek Pharmaceuticals, Inc. (0001178711) (Subject)
SC 13D/A - Paratek Pharmaceuticals, Inc. (0001178711) (Subject)
SC 13D - Paratek Pharmaceuticals, Inc. (0001178711) (Subject)
SC 13G/A - Paratek Pharmaceuticals, Inc. (0001178711) (Subject)
SC 13G/A - Paratek Pharmaceuticals, Inc. (0001178711) (Subject)
SC 13G/A - Paratek Pharmaceuticals, Inc. (0001178711) (Subject)
SC 13G/A - Paratek Pharmaceuticals, Inc. (0001178711) (Subject)
SC 13G/A - Paratek Pharmaceuticals, Inc. (0001178711) (Subject)
SC 13G - Paratek Pharmaceuticals, Inc. (0001178711) (Subject)
SC 13G - Paratek Pharmaceuticals, Inc. (0001178711) (Subject)
Jefferies resumed coverage of Paratek Pharma with a rating of Buy and set a new price target of $5.00 from $7.00 previously
BTIG Research resumed coverage of Paratek Pharma with a rating of Buy and set a new price target of $24.00
WBB Securities upgraded Paratek Pharmaceuticals from Buy to Strong Buy and set a new price target of $11.00
HC Wainwright & Co. reiterated coverage of Paratek Pharmaceuticals with a rating of Buy and set a new price target of $27.00 from $28.00 previously
HC Wainwright & Co. reiterated coverage of Paratek Pharmaceuticals with a rating of Buy and set a new price target of $28.00 from $22.00 previously
WBB Securities upgraded Paratek Pharmaceuticals from Speculative Buy to Buy and set a new price target of $10.00
Jefferies Financial Group initiated coverage of Paratek Pharmaceuticals with a rating of Buy and set a new price target of $15.00
SVB Leerink resumed coverage of Paratek Pharmaceuticals with a rating of Buy and set a new price target of $14.00
Jefferies initiated coverage of Paratek Pharma with a rating of Buy and set a new price target of $15.00
HC Wainwright resumed coverage of Paratek Pharmaceuticals with a rating of Buy
CAMBRIDGE, Mass., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Gurnet Point Capital ("Gurnet Point") and Novo Holdings A/S ("Novo Holdings") announced today the completion of their acquisition of Paratek Pharmaceuticals, Inc. ("Paratek" or the "Company") (NASDAQ:PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel therapies for life-threatening diseases and other public health threats. The Company's lead commercial product, NUZYRA® (omadacycline), is a once-daily oral and intravenous antibiotic available in the United States for the treatment of adults with community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structu
BOSTON, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. ("Paratek") (NASDAQ:PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel therapies for life-threatening diseases and other public health threats, today announced, based on a preliminary vote count, that stockholders have approved the merger agreement proposal at Paratek's special meeting of stockholders, in connection with the previously announced definitive agreement to be acquired by Gurnet Point Capital ("Gurnet Point") and Novo Holdings A/S ("Novo Holdings"). Final voting results for the special meeting will be disclosed on Form 8-K filed by Paratek with th
BOSTON, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. ("Paratek") (NASDAQ:PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel therapies for life-threatening diseases and other public health threats, today announced that a second leading independent proxy advisor Glass, Lewis & Co. ("Glass Lewis") has recommended that stockholders vote FOR the Company's previously announced definitive agreement to be acquired by Gurnet Point Capital ("Gurnet Point") and Novo Holdings A/S ("Novo Holdings"). The Glass Lewis recommendation follows the recent receipt of the recommendation from Institutional Shareholder Services Inc. (
-- NUZYRA® (omadacycline) Net U.S. Sales of $33.8 Million from the Core Commercial Business, a 35% Increase Over Second Quarter 2022 --Previously Announced Agreement to be Acquired by Gurnet Point Capital and Novo Holdings A/S; Transaction Expected to Close in the Third Quarter BOSTON, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK), ("Paratek" or "the Company"), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government and military use, today reported financial results and provided an update on corpora
Transaction Provides Paratek Stockholders with Immediate Value and Liquidity Stockholders to Receive Upfront Cash Payment of $2.15 per Share and a Contingent Value Right of $0.85 per Share on Achievement of a Commercial Milestone for a Total Potential Value of $3.00 per Share Special Meeting of Stockholders to be Held on Sept. 18, 2023 at 9 a.m. ET BOSTON, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. ("Paratek") (NASDAQ:PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel therapies for life-threatening diseases and other public health threats, today announced that it has filed definitive proxy materials and a le
Plans to Investigate All Records to Ensure Board Did Not Breach Fiduciary Duty DALLAS, July 11, 2023 /PRNewswire/ -- NexPoint Event Driven Fund today issued a demand letter to the Board of Directors of Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) (the "Company") to make available all books and records surrounding the proposed acquisition of the Company in order to investigate whether any board members breached their fiduciary duties in connection with the proposed acquisition. NexPoint Event Driven Fund is advised by NexPoint Asset Management, L.P. and together with other stockholders (collectively, "NexPoint"), are members of a group who beneficially own approximately 11.7% of the Company's
-- Third procurement to be split into two procurements based on the achievement of specific anthrax development milestones-- Next procurement expected in early 2024 BOSTON, July 10, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government and military use, today announced a modification to its Project BioShield contract with the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) wit
BOSTON, June 27, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. ("Paratek") (NASDAQ:PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel therapies for life-threatening diseases and other public health threats, today acknowledged receipt of a letter from NexPoint Asset Management, L.P., together with its affiliates (collectively, "NexPoint"). Paratek appreciates receiving constructive feedback from its stockholders and as such, has actively engaged with NexPoint over the past several months. However, Paratek's board of directors respectfully disagrees with NexPoint's characterizations contained in its letter. Paratek loo
Intends to Withhold Its Votes Against All Three Board Members Up for Election at the Annual Meeting Citing the Board's Failure to Hold Management Accountable for Years of Underperformance Plans to Carefully Scrutinize the Process Undertaken by the Board in Approving the Proposed Sale and May Vote Against the Proposed Transaction DALLAS, June 27, 2023 /PRNewswire/ -- NexPoint Asset Management, L.P., together with its affiliates (collectively, "NexPoint"), who beneficially own approximately 12% of the outstanding common stock of Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) (the "Company") today issued an open letter to the Company's Board of Directors (the "Board") announcing its plans to withh
BOSTON, June 27, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government and military use, today announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) has recommended a positive opinion for orphan medicinal product designation for NUZYRA® (omadacycline) for the treatment of nontuberculous mycobacterial (NTM) lung disease. The COMP opinion applies to all species of NTM, including Mycobacterium abscessus (MAB) and Mycobacteriu